Related Experiment Video
Updated: Jul 3, 2026
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
Expression of CYP4F2 in human liver and kidney: assessment using targeted peptide antibodies
Vandana Hirani1, Anton Yarovoy, Anita Kozeska
1Jurist Institute for Biomedical Research, Hackensack University Medical Center, 30 Prospect Avenue, Hackensack, NJ 07601, USA.
Abstract:
P450 enzymes comprising the human CYP4F gene subfamily are catalysts of eicosanoid (e.g., 20-HETE and leukotriene B4) formation and degradation, although the role that individual CYP4F proteins play in these metabolic processes is not well defined. Thus, we developed antibodies to assess the tissue-specific expression and function of CYP4F2, one of four CYP4F P450s found in human liver and kidney. Peptide antibodies elicited in rabbits to CYP4F2 amino acid residues 61-74 (WGHQGMVNPTEEG) and 65-77 (GMVNPTEEGMRVL) recognized on immunoblots only CYP4F2 and not CYP4F3b, CYP4F11 or CYP4F12. Immunoquantitation with anti-CYP4F2 peptide IgG showed highly variable CYP4F2 expression in liver (16.4+/-18.6pmol/mg microsomal protein; n=29) and kidney cortex (3.9+/-3.8 pmol/mg; n=10), with two subjects lacking the hepatic or renal enzyme entirely. CYP4F2 content in liver microsomes was significantly correlated (r> or =0.63; p<0.05) with leukotriene B4 and arachidonate omega-hydroxylase activities, which are both CYP4F2-catalyzed. Our study provides the first example of a peptide antibody that recognizes a single CYP4F P450 expressed in human liver and kidney, namely CYP4F2. Immunoquantitation and correlation analyses performed with this antibody suggest that CYP4F2 functions as a predominant LTB4 and arachidonate omega-hydroxylase in human liver.
Insights
Researchers developed specific antibodies to study CYP4F2, a key enzyme in eicosanoid metabolism. This enzyme is crucial for leukotriene B4 and arachidonate omega-hydroxylase activities in the human liver.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- The human CYP4F gene subfamily encodes P450 enzymes involved in eicosanoid metabolism.
- The specific roles of individual CYP4F proteins in these processes remain unclear.
- Understanding CYP4F2's function is vital for eicosanoid pathway research.
Purpose of the Study:
- To develop specific antibodies for assessing CYP4F2 expression and function.
- To investigate the tissue-specific distribution of CYP4F2 in human liver and kidney.
- To correlate CYP4F2 levels with specific enzymatic activities.
Main Methods:
- Generation of peptide antibodies targeting CYP4F2.
- Immunoblotting to confirm antibody specificity against CYP4F family members.
- Immunoquantitation to measure CYP4F2 levels in human liver and kidney microsomes.
- Correlation analysis between CYP4F2 content and enzymatic activities.
Main Results:
- Developed specific peptide antibodies recognizing only CYP4F2, not other CYP4F proteins.
- Demonstrated highly variable CYP4F2 expression in human liver and kidney, with some individuals lacking the enzyme.
- Found significant correlations between hepatic CYP4F2 levels and leukotriene B4 and arachidonate omega-hydroxylase activities.
Conclusions:
- This study presents the first peptide antibody capable of specifically detecting CYP4F2 in human liver and kidney.
- CYP4F2 is a predominant enzyme responsible for leukotriene B4 and arachidonate omega-hydroxylase activities in the human liver.
- The findings provide a crucial tool for further research into CYP4F2's role in eicosanoid metabolism and related diseases.
